Seeking Alpha · CMOPF · October 21, 2026

Cosmo N.V. (CMOPF) Discusses Positive Phase 2 Results and Differentiation of Rifamycin 1% Gel in Ulcerative Colitis and Proctitis Transcript

Get the app for more

Explore stock news, insights and company research.